|
MEDICIS- produced radioisotope beams for medicine MEDICIS-PROMED aims to develop a network of academic, medical and industrial partners providing an extensive doctoral program to 11 ESRs and 4 Swiss-supported ESRs in the field of new personalized treatments using radioisotope beams, notably for treatment of the deadly ovarian cancer, exploiting the newly discovered tumour endothelial marker 1 (TEM1/endosialin) for targeting the cancerous tissues. In this scheme, CERN is the coordinating partner, and collaborates with local hospitals which are able to exploit short-lived isotopes produced in the newly constructed CERN-MEDICIS facility. It fits within an extended network of high-technology companies and leading academic research institutes which will design new components for the development or tests of innovative radiopharmaceuticals and imaging agents for personalized treatment. It brings world-class researchers together in the field of lasers and isotope mass separation, accelerators, material science, oncology, entrepreneurial radiopharmaceutical production, and imaging, to propose new solutions to the 2nd deadliest cancer for women. In addition, the network will benefit from the coaching of the pioneer of personalized PET-imaging aided carbon hadron therapy recently tested in Japan. |
Coordinator: CERN, Switzerland Scientist in Charge from CERN: Full costs of the project: 2.8 M€ EU funding: 2.8 M€ EU funding for CERN: 795 k€ 1 January 2015 - 31 December 2018 |